Case Report {#sec1_1}
===========

A 12-month-old healthy girl presented with a 3-month history of a nonhealing oral ulcer and chronic diaper rash. Dermatology was consulted for evaluation of a persistent diaper rash, which had not improved after months of topical steroid and antifungal treatments. Physical examination demonstrated a thick, greasy, yellow adherent crust on the temporal scalp and behind both ears (Fig. [1](#F1){ref-type="fig"}). Intraoral examination demonstrated a 1.5-cm ulcerated lesion involving the left palatal mucosa (Fig. [2](#F2){ref-type="fig"}). There were multiple erythematous to violaceous nonblanching papules with a central hemorrhagic crust and surrounding petechiae present on the skin of the lower right abdomen (Fig. [3](#F3){ref-type="fig"}). Magnetic resonance imaging of the head revealed an enhancing lesion on the left palate in the area of the developing deciduous molar teeth and a 1.1-cm homogenous, enhancing intraosseous lesion within the right sphenoid triangle.

Biopsy specimens from the palatal lesion were received from the outside hospital and a 3-mm punch biopsy was performed on the right lower abdomen.

Diagnosis and Clinical Course {#sec1_2}
=============================

Histopathologic examination of the biopsy from the left palate ulcer demonstrated a submucosal monomorphic infiltrate composed of epithelioid cells with grooved, "coffee bean-shaped" nuclei. The epithelioid cells showed positive staining for CD1a and S100 by immunohistochemistry, consistent with a diagnosis of Langerhans cell histiocytosis (LCH) \[[@B1]\]. The erythematous papule on the right lower quadrant abdominal skin also showed a superficial dermal and focally intraepidermal infiltrate of epithelioid cells with admixed eosinophils (Fig. [4a, b](#F4){ref-type="fig"}). By immunohistochemistry, the epithelioid cells were strongly positive for CD1a, S100, and langerin (CD207) (Fig. [4c, d](#F4){ref-type="fig"}) and weakly positive for BRAFVE1. Molecular studies of the abdominal skin biopsy confirmed the presence of a BRAFV600E mutation. Magnetic resonance imaging of the head was consistent with bone involvement by LCH. The patient\'s presentation was consistent with multisystem LCH, and treatment was initiated with vinblastine and prednisone. The patient has completed 6 months of combination therapy with interval improvement in both the intraoral mass and cutaneous eruption.

Discussion {#sec1_3}
==========

LCH is a disease entity characterized by a cellular proliferation that most commonly presents in children 0--3 years old. This rare disease has an incidence of only 0.5--5.4 cases per million persons per year but represents the most common histiocytic disorder \[[@B2], [@B3], [@B4]\]. The etiology of LCH is poorly understood. Two leading theories regarding the mechanism of LCH include that it is (1) a dysfunctional immune response and (2) a clonal neoplastic process \[[@B5]\]. While some features of the disease, such as increased cytokine levels in tissue samples and an occasionally benign disease course, seem to suggest an inflammatory process, other findings, such as the monoclonal nature of the cells and characteristic mutations in BRAFV600E and MAP2K1, are supportive of a clonal neoplastic process \[[@B6], [@B7], [@B8]\].

The current classification system of LCH stratifies disease by organ involvement into single-system and multiple-system LCH \[[@B9], [@B10]\]. Single-system disease usually targets the bone, especially the skull, followed by long and flat bones. The second most commonly affected organ is the skin, representing 10% of single-system LCH involvement \[[@B11]\]. Multi-system LCH commonly affects the bone and skin, but other potential organs of involvement include the lymph nodes, bone marrow, lungs, liver, spleen, pituitary gland, and central nervous system \[[@B10]\].

The cutaneous findings of LCH include a seborrheic dermatitis-like and/or red-brown papular eruption. The seborrheic dermatitis-like eruption often manifests on the scalp, flexural neck, axilla, trunk, and perineum \[[@B12]\]. Compared to seborrheic dermatitis, LCH may have discrete papules on close examination. Furthermore, patients will fail conventional treatments for seborrheic dermatitis and have a persistent rash. On the trunk and extremities, there may be red-brown papules accompanied by erosion, crusting, and petechial or purpuric changes. Our patient presented with these classic findings, including seborrheic dermatitis-like eruption on the scalp, as well as small erythematous papules and petechiae on the trunk. Atypical vesiculopustular, molluscum-like, and "blueberry muffin" presentations have also been reported in neonates \[[@B13], [@B14]\]. Though these features were not present in our patient, LCH should be considered in a child with a diffuse rash and systemic symptoms, such as fevers and lymphadenopathy.

Given the possibility of oral mucosal and maxillofacial skeletal disease, a thorough intraoral examination is crucial when considering a diagnosis of LCH. Painful ulcers or masses, as well as either premature eruption or loss of teeth, are all potential intraoral manifestations of LCH \[[@B15], [@B16]\]. Radiographs may demonstrate diffuse bone destruction with the premature eruption, loosening, or loss of teeth. Oral mucosal involvement can lead to pain, poor feeding, and decreased oral function and may significantly impact quality of life \[[@B17], [@B18]\].

Characteristic histopathologic findings for LCH include a mononuclear cell infiltrate in the papillary dermis, sometimes also in the epidermis, and rarely in the reticular dermis, with a variable inflammatory infiltrate. Scattered eosinophils can be a common finding. The mononuclear cells are epithelioid with a nucleus that has a deep groove, often likened to a kidney bean. Immunohistochemistry demonstrates positive staining of the epithelioid cells for CD1a, langerin (CD207), and S100 and can help distinguish LCH from other histiocytic disorders \[[@B19], [@B20]\]. The neoplastic cells have an immunophenotype similar to Langerhans cells but are thought to be possibly immature Langerhans cells or possibly dendritic cells.

Timely recognition and diagnosis of LCH is important for oncologic evaluation and treatment. Initial evaluation includes basic laboratory tests and biopsy for histopathologic diagnosis. This is taken from the most easily accessible involved organ and is usually the bone or skin. Based on the initial test results, hematology-oncology may pursue further studies, including biopsy of the bone marrow, lung, or liver and computed tomography/magnetic resonance imaging to determine the extent of disease \[[@B21]\].

Treatment for LCH is dependent on disease severity. If there is no systemic involvement, isolated cutaneous disease can be managed with topical steroids. Second-line treatments include topical tacrolimus, nitrogen mustard, imiquimod, narrowband ultraviolet B radiation, and psoralen and ultraviolet A radiation \[[@B5]\]. However, in pediatric patients, psoralen and ultraviolet A radiation should not be used due to increased risk for secondary malignancies \[[@B22], [@B23], [@B24]\]. Systemic treatment is reserved for patients with multisystem disease. One-year combination therapy with mercaptopurine, vinblastine, and prednisone is superior to shorter courses of treatment \[[@B25]\]. Initial success has been reported with the BRAF inhibitor vemurafenib for LCH with BRAFV600E mutations \[[@B26]\].

The prognosis of LCH depends on a variety of factors, including age, number of involved organs, and initial treatment response. Young patients who are less than 2 years of age can present with more acute, disseminated disease. While the vast majority of patients with isolated cutaneous findings have progression-free survival at 3 years, less than half of the patients with multisystem disease are in remission at 3 years \[[@B10], [@B11], [@B27]\]. Notably, "high-risk" organ involvement, specifically of the hematopoietic system, central nervous system, liver, and spleen, portends a poor prognosis \[[@B28]\]. The failure to respond to initial chemotherapy after the initial 6--12 weeks of treatment is also a poor prognostic marker \[[@B10]\]. Our patient has several risk factors for poor prognosis, including an age younger than 2 years at initial presentation and multisystem disease. However, she lacks "high-risk" organ involvement and has exhibited initial response to treatment. Long-term, close clinical follow-up is required in all patients with single- and multi-system disease, given the possibility of progression to systemic disease and/or relapse after remission.

This case highlights the fundamental concepts in the diagnosis, treatment, and management of LCH, a condition that most commonly presents in young children. When a child presents with a recalcitrant seborrheic dermatitis-like eruption or chronic diaper rash, the clinician should be alerted to the possibility of LCH to prevent a delay in diagnosis and treatment.
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![**a** Superficial dermal mononuclear infiltrate (HE, original magnification ×10). **b** Superficial dermal histiocytic infiltrate with eosinophils (HE, original magnification ×20). **c** Positive immunohistochemical staining for CD1a (original magnification ×20). **d** Positive immunohistochemical staining for langerin (original magnification ×20).](dpa-0004-0024-g04){#F4}
